Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2014-02-27 Annual Report
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 61 pages 592.8KB
Annual Report Classification · 95% confidence The document is titled 'Cyclopharm Limited Appendix 4E' and is described as a 'Preliminary Final Report For the year ended 31 December 2013.' It contains detailed financial performance data, including revenues, losses, segmental sales, and commentary on results for the full year. The document includes a Managing Director's Report with operational and regional reviews, financial figures, and discussion of business activities. The length is substantial (15,000 characters), and it contains actual financial data and analysis for a full fiscal year. Appendix 4E is a known Australian regulatory form used for preliminary final reports, which are equivalent to annual reports or full-year financial disclosures. The document is not merely an announcement of a report but contains substantive financial information and management commentary. Therefore, it fits the definition of an Annual Report (10-K equivalent). FY 2013
2014-02-27 English
Change of Director's Interest Notice 3 pages 116.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares held before and after the change, the nature of the change (on-market trade), and related parties. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of Director's Dealing filings.
2013-12-22 English
Japanese Regulatory Approval received 2 pages 213.9KB
Capital/Financing Update Classification · 90% confidence The document is a company announcement dated 25 October 2013 from Cyclopharm Limited, reporting that their TechnegasPlus Generator has received Japanese regulatory approval for clinical use. The text focuses on the approval news, market context, and expected commercial impact. There are no financial statements, detailed financial data, or comprehensive report content. The document is relatively short (3891 characters) and reads as a press release or announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications. The content is an update on a regulatory approval event, which aligns best with a Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's commercial prospects and potential revenue streams. Therefore, the most appropriate classification is CAP with high confidence.
2013-10-24 English
Chairman to Stand Down Temporarily 1 page 119.1KB
Board/Management Information Classification · 100% confidence The document is a short announcement dated 23 October 2013 from Cyclopharm Limited regarding a change in the status of a board member, specifically the Chairman stepping down temporarily and being redesignated as a Non-Executive Director. It also announces the appointment of an acting Chairman. There is no financial data, no mention of a report or financial results, and the content focuses solely on board/management changes. The document length is only 1806 characters, indicating it is a brief announcement rather than a detailed report. Therefore, the appropriate classification is Board/Management Information (MANG).
2013-10-22 English
Change of Director's Interest Notice 3 pages 115.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the change, and related parties. This type of document is a formal notification of personal share transactions by company directors. It is not a financial report, earnings release, or management discussion. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is a full notice rather than a brief announcement or certification.
2013-10-20 English
Letter to Shareholders 1 page 129.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Cyclopharm Limited regarding a charge against its Chairman unrelated to the company's business. It does not contain financial data, report details, or regulatory filings about company performance or governance changes. It is a general regulatory announcement to inform the market about a non-business related issue involving a director. The document length is only 1477 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general market update that does not fit other specific categories.
2013-10-16 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.